<div><div><p>[SINGAPORE] Home-grown biotech firm Mirxes will join the Hang Seng Composite Index on Sep 8, the startup announced on Saturday (Aug 23).</p><p>The Hang Seng Composite Index is a benchmark which covers about 95 per cent of the total market capitalisation of companies listed on the Hong Kong mainboard. It includes top Chinese companies such as Alibaba and Tencent. </p><p>“This significant milestone elevates the company’s market profile and enhances its strategic position within the Hong Kong and wider Asian capital markets,” said Mirxes. </p><div><div><div><div id="dfp-ad-imu1"></div></div></div></div><p>“Inclusion in the Hang Seng Composite Index is a powerful testament to Mirxes’ strong market position and solid performance since its listing on the Hong Kong Stock Exchange three months ago.” </p><p>Shares of Mirxes opened at HK$23.30 on May 23, and last traded at HK$45.82 on Friday. </p><p>Mirxes added that it expects its addition to the index to significantly increase the company’s visibility and trading liquidity, making its shares more attractive to a broader base of investors, including institutional funds and index-tracking exchange-traded funds.</p><div><div><div><div id="dfp-ad-midarticlespecial"></div></div></div></div><p>The inclusion may also enable the company’s shares to be traded among “a vast pool of investors in mainland China” through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect schemes.</p><p>This would provide it with access to a crucial new source of capital to support its long-term growth and innovation pipeline, noted Mirxes.</p><p>Mirxes, founded in 2014, focuses on microRNA-based cancer detection. Its flagship product, GastroClear, is the world’s first molecular blood test approved for early detection of gastric cancer in high-risk populations.</p></div><div>MirxesBiotech</div><div><section><section><p>Share with us your feedback on BT's products and services</p><div>Feedback</div></section></section></div><div><div><div><div id="dfp-ad-imu2"></div></div></div></div></div>

02629

<p>总部位于新加坡的生物科技公司 Mirxes 将于 9 月 8 日加入恒生综合指数，提升其在亚洲资本市场的市场形象和战略地位。该指数包括阿里巴巴和腾讯等主要公司，Mirxes 预计将获得更高的知名度和交易流动性，吸引更广泛的投资者基础。Mirxes 成立于 2014 年，专注于基于微小 RNA 的癌症检测，其旗舰产品 GastroClear 是首个获得批准的早期胃癌检测分子血液测试</p>

总部位于新加坡的 Mirxes 将加入阿里巴巴和腾讯，成为恒生综合指数的一部分